Summary: Researchers uncovered a precise molecular mechanism to restore NMDA receptor (NMDAR) hypofunction, a core pathology in autism spectrum disorder (ASD). The research shifts focus away from traditional, highly toxic systemic targets toward Slc6a20a/SLC6A20, a glycine transporter heavily localized within cognition-related brain regions like the cortex and hippocampus.
Utilizing antisense oligonucleotides (ASOs) in adult mouse models with SHANK2 and SHANK3 mutations, as well as human cortical organoids, the team successfully normalized NMDAR activity, corrected synaptic phosphorylation signaling cascades, and reversed deep-seated behavioral deficits without triggering standard brainstem respiratory side effects.
Key Facts
- The NMDAR Activation Dilemma: The NMDA receptor requires both glutamate and glycine to fully trigger. While NMDAR hypofunction drives multiple brain disorders—including ASD, schizophrenia, and intellectual disabilities, previous clinical trials failed because they targeted GlyT1, a glycine transporter dense in the brainstem, causing dangerous respiratory and motor side effects.
- Localization-Driven Safety Precision: To solve this, the IBS team targeted Slc6a20a, a distinct glycine transporter highly concentrated within higher-order cognitive zones (cortex and hippocampus) while remaining safely sparse in brainstem motor centers.
- Adult Behavior and Social Rescue: Administered to adult mice carrying mutations in major autism-risk genes SHANK2 and SHANK3 (models for Phelan-McDermid syndrome), a localized Slc6a20a-ASO successfully boosted NMDAR activity. The intervention reversed entrenched adult behavioral phenotypes, including deficits in social interaction, communication impairments, and repetitive motor loops.
- The Phospho-Proteomic Mechanism: Large-scale phospho-proteomic analysis revealed that the ASO does not simply change total protein numbers. Instead, it systematically normalizes abnormal phosphorylation patterns across critical synaptic signaling proteins and NMDAR regulatory networks.
- Human Cortical Organoid Validation: To confirm human translational viability, the team used CRISPR gene editing to build human cortical organoids with SHANK2 and SHANK3 mutations. Applying a human-targeted SLC6A20-ASO successfully restored NMDAR function back to near-normal baseline parameters.
- Extended Therapeutic Window Durability: A single dosing regimen of the engineered ASO sustained its neuroprotective efficacy for at least 8 weeks in vivo, demonstrating long-term operational stability with zero detectable adverse effects or toxicity trends.
- Broader Neuropsychiatric Utility: Because it targets endogenous signaling pathways rather than complex gene re-expression, this SLC6A20 paradigm offers a scalable template to treat an array of neuropsychiatric conditions anchored by NMDAR hypofunction, including schizophrenia.
Source: Institute of Basic Science
Researchers have identified a promising new therapeutic strategy for autism spectrum disorder (ASD). A research team led by Director KIM Eunjoon of the IBS Center for Synaptic Brain Dysfunctions has now identified a promising new strategy for restoring NMDA receptor (NMDAR) function by targeting a glycine transporter called Slc6a20a/SLC6A20.
Impaired NMDAR function has long been implicated in a range of brain disorders, including autism spectrum disorder (ASD), schizophrenia, intellectual disability, and NMDAR encephalitis. Despite decades of research, attempts to restore NMDAR activity have produced mixed clinical results, highlighting the need for more precise therapeutic approaches.
The NMDA receptor requires not only glutamate but also glycine to become fully activated. Previous therapeutic approaches attempted to increase glycine levels by inhibiting GlyT1, another glycine transporter. However, because GlyT1 is widely expressed in brainstem regions involved in breathing and motor control, such treatments often produced limited benefits and undesirable side effects.
The researchers instead focused on Slc6a20a, a glycine transporter predominantly expressed in cognition-related brain regions such as the cortex and hippocampus.
Using antisense oligonucleotides (ASOs) to suppress Slc6a20a expression, the team investigated whether NMDAR function could be restored in mouse models carrying mutations in SHANK2 and SHANK3, two major autism-risk genes that are also associated with Phelan-McDermid syndrome and other neurodevelopmental disorders.
The results showed that Slc6a20a-ASO successfully restored NMDAR activity in multiple autism-related mouse models. The treatment also improved several behavioral abnormalities, including impairments in social interaction, social communication, and repetitive behaviors. Importantly, these therapeutic effects were observed in adult animals, suggesting that correction of NMDAR dysfunction may remain possible even after key stages of brain development have passed.
To understand the underlying mechanism, the researchers performed large-scale phospho-proteomic analyses. Surprisingly, the treatment had relatively little effect on overall protein abundance. Instead, it restored abnormal phosphorylation patterns in proteins involved in synaptic signaling and NMDA receptor regulation, suggesting that the therapy works by normalizing protein function rather than simply changing protein levels.
To evaluate its translational potential, the team extended the study to human brain models.
Using CRISPR gene editing, the researchers generated human cortical organoids carrying SHANK2 or SHANK3 mutations. These organoids exhibited reduced NMDAR activity similar to that observed in the mouse models. Treatment with an ASO targeting the human SLC6A20 gene restored NMDAR function to near-normal levels.
“Unlike gene re-expression strategies, SLC6A20 inhibition works by modulating endogenous signaling pathways and may offer a more practical therapeutic route,” said Director KIM Eunjoon. “The fact that the effect was reproduced not only in mice but also in human cortical organoids suggests that this approach may represent a promising therapeutic strategy for neurodevelopmental disorders characterized by NMDA receptor hypofunction.”
The researchers also found that a single administration of the ASO remained effective for at least 8 weeks without detectable adverse effects in the treated mice.
Beyond autism spectrum disorder, the findings may have broader implications for other neurological and psychiatric conditions associated with reduced NMDAR activity, including schizophrenia and certain forms of intellectual disability.
The findings establish SLC6A20 as a promising therapeutic target for restoring NMDAR function and provide a potential framework for treating a broader range of neurodevelopmental and neuropsychiatric disorders linked to NMDAR hypofunction.
Key Questions Answered:
A: Because older therapies targeted a glycine transporter called GlyT1, which is found all over the brainstem. While trying to fix cognitive issues, these drugs accidentally interfered with the brainstem’s primitive survival centers, causing severe respiratory and motor control problems that ruined clinical trials.
A: Through anatomical precision. The SLC6A20 glycine transporter is predominantly expressed in the brain’s higher-order cognitive regions, like the cortex and hippocampus, and is largely absent in the brainstem. By using Antisense Oligonucleotides (ASOs) to silence this specific gene, researchers can boost localized glycine levels exactly where thinking and socializing occur, leaving breathing circuits untouched.
A: No, the study showed profound success in fully mature subjects. When the IBS team treated adult mice with established autism behaviors, the single-dose ASO treatment successfully restored receptor function and corrected social communication impairments and repetitive actions. This proves that fixing NMDAR dysfunction remains highly effective long after key childhood brain development windows have closed.
